ECE2013 Poster Presentations Diabetes (151 abstracts)
Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes
Marco Zavattaro 2 , Flavia Prodam 1, , Maria Grazia Mauri 2 , Loredana Pagano 2 , Marina Caputo 2 , Sara Belcastro 2 , Gabriele Allochis 2 & Gianluca Aimaretti 2
1Department of Health Sciences, Novara, Italy; 2Department of Translational Medicine, Novara, Italy.
Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.
Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatment, or patients intolerant to metformin were recruited. Exclusion criteria were: the presence of kidney diseases on dialysis, lack of compliance or refusal to injective therapy. Changes in systolic (SBP) and diastolic blood pressure (DBP) and cardiovascular risk scores (Framingham and UKPDS algorithms) were evaluated. 243 subjects (110 males; 133 females) were consecutively recruited (age, mean±S.D. 59.6±10.4 years; disease duration 8.3±7.0 years).
Results: Both SBP (154.7±22.0 vs 143.5±23.6 mmHg, P<0.0001) and DBP (89.1±11.5 vs 84.4±10.7 mmHg, P<0.0001) decreased respect to baseline. Both reductions were independent of changes in glucose, HbA1c and anti-hypertensive drugs. Framingham risk score decreased at 12 months respect to baseline (30.2±17.9 vs 35.6±20.3%, P<0.0001). At the same time a reduction in the risk of coronary events (15.7±11.4 vs 20.7±15.2%, P<0.0001) and of fatal coronary events (10.9±9.5 vs 15.2±13.8%, P<0.0001) was recorded. Finally, also the risk of stroke (8.6±8.5 vs 12.0±15.3%, P<0.0001) and fatal stroke (1.4±1.5 vs 2.3±3.3%, P<0.0001) at 12 months decreased respect to baseline. During the 12 months of observation no cardiovascular accidents occurred.
Conclusion: Liraglutide is effective in reducing blood pressure and cardiovascular risk in patients with DM2 in a relatively short-time treatment.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more